Tingjie Guo
Assistant Professor
- Name
- Dr. T. Guo
- Telephone
- +31 71 527 4501
- t.guo@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0002-7892-6220
Currently working at Leiden University, Dr. Tingjie Guo specializes in pharmacometrics research, focusing on bacteriophage and oncolytic virotherapy and central nervous system infections. Besides research, He coordinates the PKPD course and contributes to various courses in computational subjects for the Bio-pharmaceutical sciences bachelor's and master’s programs.
More information about Tingjie Guo
PhD Candidates
News
-
During the next pandemic, this mathematical model will speed up the search for treatment -
Dutch Research Council Open Science Fund grants for five Leiden projects -
ENW grant from the Dutch Research Council (NWO): Reversing antimicrobial resistance using bacteriophage -
Grant Elise Mathilde Fund & LUF: Using virus to kill bacteria: design of innovative phage-antibiotic combination treatments to combat antimicrobial resistance
My academic journey began at Peking University, where I obtained my BSc in Pharmaceutical Sciences in 2014 and a MSc in Pharmacometrics in 2016. I then moved to Amsterdam to pursue my PhD at Amsterdam UMC (at the time VUmc). During this phase, I strengthened my expertise in pharmacometrics in the area of model-informed precision dosing and obtained substantial experience in developing clinical decision support systems. I played a central role in designing and realizing AutoKinetics, a software package for real-time dose advice. After completing my PhD in 2021, I continued my academic pursuit as an assistant professor at Leiden University.
My research focuses on using computational methods, especially pharmacometrics, to enhance our understanding of the interactions between therapeutic agents, pathogens, and biological systems. My goal is to translate theoretical and experimental findings into clinical implementations to ultimately benefit patient care. I am currently developing research in virotherapy and central nervous system (CNS) infections.
Virotherapy is a novel therapeutic approach that utilizes either natural or engineered viruses for therapeutic purposes. In this treatment, viruses that are highly specific to certain host cells are administered to patients and they can infect, replicate and eventually destroy the host cells. For instance, in the treatment of bacterial infections, bacteriophages target and eliminate bacterial pathogens, while in cancer therapy, oncolytic viruses aim to eradicate tumor cells. I aim to use sophisticated mathematical models to describe and predict the virus behavior based on experimental and/or clinical data so that we can manage virotherapy more effectively and formulate optimal treatment strategies.
CNS infections such as meningitis, encephalitis, and brain abscesses are severe clinical complications which can cause long-term neurological damage impairing cognitive and motor functions. Understanding and addressing CNS infections remain urgent. However, the presence of blood-brain-barrier (BBB) often hampers drug distribution into the brain, rendering many treatments ineffective. I aim to develop mechanistic models to reveal the pharmacokinetic and pharmacodynamic behavior of drugs in their interactions with BBB to support treatment optimization and drug development for CNS infection.
Alongside my research activities, I am also actively engaged in education. I coordinate the PKPD course for the Bachelor's program in Biopharmaceutical Sciences and lecture on various topics within pharmacometric and computational subjects at different levels.
Assistant Professor
- Faculty of Science
- Leiden Academic Centre for Drug Research
- LACDR/Pharmacology
- Mehta K.M., Guo T. & Graaf P.H. van der Hasselt J.G.C. van (2024), Model‐based dose optimization framework for bedaquiline, pretomanid, and linezolid for the treatment of drug‐resistant tuberculosis, British Journal of Clinical Pharmacology 90(2): 463-474.
- Zwep L.B., Guo T., Nagler T.W., Knibbe C.A.J., Meulman J.J. & Hasselt J.G.C. van (2024), Virtual patient simulation using copula modeling, Clinical Pharmacology & Therapeutics 115(4): 795-804.
- Mehta K.M., Balazki P., Graaf P.H. van der, Guo T. & Hasselt J.G.C. van (2024), Predictions of bedaquiline central nervous system exposure in patients with tuberculosis meningitis using physiologically based pharmacokinetic modeling, Clinical Pharmacokinetics 63: 657-668.
- Sun M.,Manson M.L., Guo T. & Lange E.C.M. de (2024), CNS viral infections—what to consider for improving drug treatment: a plea for using mathematical modeling approaches, CNS Drugs 38(5): 349-373.
- Guo Y., Guo T., Knibbe C.A.J., Zwep L.B. & Hasselt J.G.C. van (2024), Generation of realistic virtual adult populations using a model-based copula approach, Journal of Pharmacokinetics and Pharmacodynamics 51: 735-746.
- Fu Y., Snelder N., Guo T., Graaf P.H. van der & Hasselt J.G.C. van (2023), Evaluation of a cardiovascular systems model for design and analysis of hemodynamic safety studies, Pharmaceutics 15(4): 1175.
- Mehta K.M., Guo T., Graaf P.H. van der & Hasselt J.G.C. van (2023), Predictions of bedaquiline and pretomanid target attainment in lung lesions of tuberculosis patients using translational minimal physiologically based pharmacokinetic modeling, Clinical Pharmacokinetics 62(3): 519-532.
- Guo T., Abdulla A., Koch B.C.P., Hassel J.G.C. van, Endeman H., Schouten J.A., Elbers P.W.G., Brüggeman R.J.M. & Hest R.M. (2022), Pooled population pharmacokinetic analysis for exploring ciprofloxacin pharmacokinetic variability in intensive care patients, Clinical Pharmacokinetics 61(6): 869-879.
- Liu F., Aulin L.B.S., Guo T., Krekels E.H.J., Moerland M., Graaf P.H. van der & Hasselt J.G.C. van (2022), Modelling inflammatory biomarker dynamics in a human lipopolysaccharide (LPS) challenge study using delay differential equations, British Journal of Clinical Pharmacology 88(12): 5420-5427.
- Mehta K.M., Guo T., Wallis R.S., Graaf P.H. van der & Hasselt J.G.C. van (2022), Quantitative systems pharmacology modeling framework of autophagy in tuberculosis: application to adjunctive metformin host-directed therapy, Antimicrobial Agents and Chemotherapy 66(8): e0036622.
- Zwep L.B., Duisters K.L.W., Jansen M., Guo T., Meulman J.J., Upadhyay P. & Hasselt J.G.C. (2021), Identification of high‐dimensional omics‐derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling, CPT: Pharmacometrics and Systems Pharmacology 10(4): 350-361.
- Guo T.J., Hest R.M. van, Zwep L.B., Roggeveen L.F., Fleuren L.M., Bosman R.J., Voort P.H.J. van der, Girbes A.R.J., Mathot R.A.A., Elbers P.W.G. & Hasselt J.G.C. van (2020), Optimizing predictive performance of bayesian forecasting for vancomycin concentration in intensive care patients, Pharmaceutical Research 37: 171.
- Bestuurder